ESALF - Gilead's Jyseleca Ok'd in Japan for rheumatoid arthritis

Japan's Ministry of Health, Labor and Welfare has approve Gilead's (GILD) Jyseleca (filgotinib 200 mg and 100 mg tablets), a once-daily, oral, JAK1 inhibitor for the treatment of rheumatoid arthritis ((RA)) who did not respond to conventional therapies.Gilead will hold the marketing authorization of Jyseleca in Japan and supply the product, while Eisai (ESALF) will manage distribution.Gilead is developing Jyseleca in collaboration with Galapagos (GLPG).Last month, Galapagos and Gilead announced FDA CRL for filgotinib for RA as the agency requested for more data and review period extended into 2021.

For further details see:

Gilead's Jyseleca Ok'd in Japan for rheumatoid arthritis